Statement of Principles concerning vascular neurocognitive disorder (Reasonable Hypothesis) (No. 9 of 2023)

The instrument pivots on a small set of interlocking legal and medical concepts that govern how claims for vascular neurocognitive disorder are assessed under the VEA and MRCA. The central legal frame is the “reasonable hypothesis” standard embedded in the Repatriation Medical Authority’s powers under subsection 196B(2) VEA, which this instrument implements by stating the medical criteria and relevant factors which, if present, will as a minimum raise the reasonable hypothesis connecting the disorder to service (see s 3, s 9 heading).

Clinically, the instrument defines vascular neurocognitive disorder by reference to DSM‑5‑TR criteria (s 7(2), Schedule 1). The DSM‑derived framework requires evidence of either major neurocognitive disorder or mild neurocognitive disorder, with clinical features consistent with a vascular aetiology, and evidence of cerebrovascular disease from history, examination or neuroimaging sufficient to account for the deficits (s 7(2) A-C). The instrument lists included subtypes such as Binswanger disease, multi‑infarct dementia, post‑stroke dementia and strategic infarct dementia (s 7(2) D(i)-(vii)). It also enumerates exclusions so that deficits primarily due to delirium, another mental disorder, inherited diffuse white matter disease, neurodegenerative disease, brain tumour, subdural haematoma, substance effects, or systemic disorders are not labelled vascular neurocognitive disorder under this instrument (s 7(2) E(i)-(iii)).

A further concept is the interaction between clinical onset and clinical worsening. The factors in s 9 are duplicated in two temporal frames: factors that must exist before the clinical onset of vascular neurocognitive disorder (s 9(1)-(19)) and nearly identical factors that must exist before clinical worsening of the disorder (s 9(20)-(38)). That structure recognises two different causal questions used in administrative law under the VEA and MRCA , whether service materially contributed to the disorder’s initial occurrence or to its later deterioration. The instrument also contains an explicit factor covering an inability to obtain appropriate clinical management for the disorder (s 9(39)).

Conceptual precision is supplied in Schedule 1. Many of the factors rely on numerical thresholds and operational tests: dyslipidaemia is defined by specific lipid values or the regular administration of lipid‑normalising therapy; obesity is BMI ≥ 30 using the formula W/H2; one pack‑year is quantified and examples for calculation are provided; ambient chronically polluted air is defined by PM2.5 annual concentrations above 25 µg/m3; chronic kidney disease is defined by GFR below 60 ml/min/1.73 m2 for 3 months, albuminuria, biopsy/imaging evidence, or kidney transplant (Schedule 1). Neuroimaging is defined as an image usually obtained at a date after the clinical onset (Schedule 1).

Finally, the instrument explicitly notes the relation to classification systems: it states that vascular neurocognitive disorder attracts ICD‑10‑AM code F01 but that for application of the Statement the meaning is that given in subsection 7(2) (s 7(3)-(4)). That signals that administrative assessment is governed by the instrument’s substantive DSM‑based criteria rather than by automatic reliance on ICD coding alone.

This Statement of Principles affects several discrete groups, each with distinct roles and burdens under the instrument. Primary beneficiaries or claimants are veterans, members of Peacekeeping Forces, and members of the Forces whose claims fall within the VEA or MRCA frameworks. The instrument explicitly applies to any claim to which section 120A of the VEA or section 338 of the MRCA applies (s 5). Those statutory sections set out eligibility criteria for claims; this Statement provides the medical basis used by administrative decision makers to determine whether a reasonable hypothesis exists connecting vascular neurocognitive disorder or death from it to relevant service.

Administrative decision makers and medical advisers within the Department of Veterans’ Affairs and the Repatriation Medical Authority are affected in how they assess and adjudicate claims. The Repatriation Medical Authority made the instrument under s 196B(2) VEA (s 3) and expressly states its view that sound medical‑scientific evidence supports the relationship between vascular neurocognitive disorder and relevant service (s 8). While the instrument does not itself mandate a specific administrative process, it establishes the factors that claim handlers must consider when assessing whether the reasonable hypothesis test is met. It also instructs that, where a factor refers to an injury or disease covered by another Statement, the other Statement applies (s 11). That interdependency affects the way decision makers combine multiple Statements in complex cases.

Medical practitioners who prepare reports and provide diagnostic, imaging and laboratory evidence are affected because the instrument specifies the type and timing of evidence that will be material. For example, neuroimaging showing white matter lesions, haemorrhage or infarction is a listed factor (s 9(2), s 9(21)), and laboratory definitions for dyslipidaemia, hyperhomocysteinaemia, albuminuria and chronic kidney disease are set out in the Schedule 1 dictionary. Practitioners will be asked to verify dates for clinical onset or worsening so that temporal windows and duration thresholds (for example, 5 years for diabetes or depressive disorder, 20 years for smoking cessation) can be applied (s 9).

Legal advisors, advocates and medical-legal experts who prepare claims and represent veterans are affected by the specificity of the instrument. The list of factors, the temporal requirements and the defined thresholds mean that claim preparation will generally require precise documentary evidence rather than general statements of history. For example, smoking must meet the defined pack‑year threshold and onset dates (s 9(10), 9(29)); obesity must be demonstrated for periods of at least 5 years within a 20 year window (s 9(12), 9(31) and Schedule 1).

Finally, the instrument has indirect effects on parties providing ongoing treatment and rehabilitation. The inclusion of a factor covering inability to obtain appropriate clinical management (s 9(39)) may bring systemic access issues into claims; providers and administrators of health services may therefore find their records and statements called upon to establish whether adequate management was available.

This Statement of Principles does not itself create statutory duties in the sense of criminal penalties or new civil obligations. Rather, it creates a set of medical‑evidentiary standards for administrative determination of entitlement claims under the VEA and MRCA. The instrument therefore establishes rights and procedural bearings within the administrative claim context.

Rights for claimants. Claimants have the right to have their vascular neurocognitive disorder claims assessed using the criteria and factors specified in this instrument where the claim falls within the applicable VEA or MRCA provisions (s 5). That means a claimant can rely on evidence that matches the instrument’s factors to establish that a reasonable hypothesis exists linking their condition to service. When a factor in s 9 refers to another Statement of Principles, the claimant benefits from the application of the separate Statement in accordance with its terms (s 11).

Duties of administrative decision makers. The Repatriation Medical Authority determined the Statement under its statutory power (s 3), and decision makers who adjudicate claims within the VEA and MRCA frameworks will use the Statement to test the reasonable hypothesis threshold. The instrument places no explicit statutory duty language in its text for decision makers; its operative effect is that the listed factors must exist as a minimum before a reasonable hypothesis is raised (s 9). Section 10(1) requires that any listed factor be related to the person’s relevant service, so decision makers must consider the relationship to service rather than merely the presence of a factor.

Evidence duties on clinicians and experts. The instrument sets out the kinds of evidence that will be relevant and in many cases prescribes numerical or temporal thresholds (Schedule 1; s 9). Clinicians providing reports therefore have the practical duty, as a matter of claim preparation, to document dates, numeric test results, imaging reports and longitudinal records that match the definitions in the Schedule. For example, dyslipidaemia must be evidenced by lipid values or medication records (Schedule 1); chronic kidney disease must be supported by GFR measures, albuminuria testing or biopsy/imaging evidence (Schedule 1).

Interactional rights with other Statements. Where a factor in s 9 refers to an injury or disease governed by another Statement, the rights established under that other Statement apply (s 11). That creates a right for claimants to have cross‑referenced medical conditions assessed under the specialised criteria of other Statements, rather than being shoehorned into this Statement’s definitions.

Limits and scope. The instrument does not itself grant a monetary entitlement, nor does it set out review rights, appeal mechanisms, or administrative timelines. Those procedural rights remain governed by the VEA and MRCA and by administrative law; the Statement’s role is to define the medical threshold for a reasonable hypothesis and the evidentiary content that supports it (s 8, s 9). The instrument’s precise temporal and numeric thresholds mean that the claimant’s right to an acceptance of causal connection depends on assembling evidence that meets those defined minima.

The instrument contains no penal provisions, fines, or direct enforcement mechanisms. It is a medical‑scientific determination made under subsection 196B(2) of the Veterans' Entitlements Act 1986 (s 3), and its enforcement is administrative rather than criminal. The primary enforcement mechanism is operational: the Statement of Principles supplies the medical framework that decision makers and advisers use when assessing claims under the VEA and MRCA (s 5).

What the instrument does enforce indirectly is the evidentiary threshold for establishing a “reasonable hypothesis” that vascular neurocognitive disorder is connected to relevant service. Section 9 frames the factors that must exist as a minimum before such a reasonable hypothesis can be said to be raised. Administrative decision makers will therefore use those factors as the baseline for acceptance or rejection of the causal link; the result will determine whether the claimant proceeds to the next stage of entitlement assessment under the VEA or MRCA processes. The instrument does not itself specify remediatory steps where a claim is rejected, nor does it set out appeal procedures; those processes are governed by the VEA, MRCA and the normal administrative review and merits review mechanisms operating in the veterans’ claims system.

Compliance monitoring and evidentiary consequences. The Schedule contains precise, testable definitions for many factors , for example dyslipidaemia by lipid values, chronic kidney disease by GFR or albuminuria, obesity by BMI, pack‑year calculation for smoking, and PM2.5 thresholds for ambient pollution exposure (Schedule 1). The practical enforcement effect is that claimants who cannot provide documentary evidence matching these definitions will be less likely to meet the instrument’s minima. The Repatriation Medical Authority’s view that there is sound medical‑scientific evidence supporting the relationships specified (s 8) establishes the medical benchmark against which administrative determinations are made.

No administrative sanctions for third parties. The instrument does not create obligations that attract penalties for medical practitioners, employers, health services, or other third parties. Nevertheless, records held by those parties will be material evidence for claims, and their availability or absence will affect the administrative outcome. The instrument also does not purport to regulate clinical standards of care; rather, it treats the availability or absence of appropriate clinical management as an evidentiary factor (s 9(39)).

This Statement is an instrument made under subsection 196B(2) of the Veterans’ Entitlements Act 1986 (s 3), and it interacts directly with statutory claim processes under both the VEA and the MRCA. Section 5 expressly limits the instrument’s application to claims to which section 120A of the VEA or section 338 of the MRCA applies. Those statutory sections, which are not reproduced in this instrument, set out the particular grounds for establishing liability and the procedural context for entitlement claims; this Statement supplies the medical criteria decision makers will apply within those statutory frameworks.

The instrument cross‑references and interacts with other Repatriation Medical Authority Statements of Principles. Section 11 provides that if a factor in s 9 is an injury or disease for which another Statement has been determined under subsection 196B(2) of the VEA, that other Statement applies in accordance with its own terms. In practice this creates an interlocking network of Statements where diseases that are comorbid or part of causal chains are assessed under the most relevant specialised Statement. Decision makers must therefore consult multiple Statements where factors overlap.

The instrument also engages external clinical classification systems. It notes that vascular neurocognitive disorder attracts ICD‑10‑AM code F01, but it states that the meaning for application of the Statement is the DSM‑5‑TR derived definition set out in subsection 7(2) (s 7(3)-(4)). That establishes a hierarchy for administrative purposes: although ICD coding is acknowledged, the DSM‑based criteria in the instrument govern entitlement assessment.

References to diagnostic manuals and national datasets. The instrument explicitly adopts DSM‑5‑TR definitions and cites the manual in the Schedule (Schedule 1). It also refers to The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD‑10‑AM) in s 7(4). Those references mean that clinicians and decision makers will need to map clinical findings and diagnostic codes to the instrument’s DSM‑based criteria and the Schedule’s numeric thresholds.

Overlap with general administrative law. While the instrument itself does not establish appeals or review processes, it functions within administrative decision making under the VEA and MRCA where judicial and merits review processes apply. Decisions that apply this Statement will be susceptible to administrative law principles, including procedural fairness and review on questions of law. The Statement of Principles will therefore be part of the evidentiary record and legal reasoning in any such reviews, though the instrument does not by itself set out those remedies.

Interaction with clinical and public health law. Some factors use public health metrics , for example “ambient, chronically polluted air as specified” is defined by PM2.5 annual averages exceeding 25 µg/m3 (Schedule 1). Establishing environmental exposure for a claimant may therefore require reference to environmental monitoring data and potentially to other statutory frameworks that regulate air quality. Similarly, clinical definitions such as chronic kidney disease rely on laboratory tests and diagnostic criteria that are governed by clinical practice guidelines rather than by statute, but are nevertheless invoked by the instrument for administrative purposes.

The instrument itself provides a concise amendment history within its operative provisions. It is the Statement of Principles No. 9 of 2023 concerning vascular neurocognitive disorder. The instrument was dated 27 February 2023 (document header) and commenced operation on 27 March 2023 (s 2). Section 4 explicitly repeals the previous Statement of Principles concerning vascular dementia No. 78 of 2014 (Federal Register of Legislation No. F2014L01140). The effect of the repeal is that the No. 78 of 2014 Statement ceases to apply; the new Statement replaces it as the operative Repatriation Medical Authority determination under subsection 196B(2).

No further amendments or historical iterations are included in the text provided. The instrument contains a footnote style Note referencing the effective date and ISBN for the ICD‑10‑AM Tenth Edition (s 7(4)), but that is a citation rather than an amendment. The Schedule contains definitions that may reflect updated clinical thresholds or the adoption of DSM‑5‑TR terminology, indicating a substantive update from the prior 2014 Statement which used older nomenclature (the 2014 Statement name referenced vascular dementia). The new Statement modernises the clinical lexicon by expressly stating that the diagnosis is derived from DSM‑5‑TR and by including contemporary environmental exposure thresholds such as PM2.5 levels.

For future amendments or repeals, the statutory mechanism remains subsection 196B(2) of the VEA; any future Repatriation Medical Authority determination made under that power would amend or replace this instrument by express repeal or by issuing a subsequent instrument. The instrument does not set out transitional provisions; therefore, the operational commencement date in s 2 is the effective date for application to claims subject to the VEA and MRCA sections specified in s 5. Practitioners should note the explicit repeal in s 4 when comparing decisions made under the 2014 Statement with decisions made after 27 March 2023.

The instrument does not record any litigation history. It is a Repatriation Medical Authority Statement of Principles made under subsection 196B(2) of the VEA (s 3). The text contains no references to prior cases, tribunal decisions, or judicial interpretations of the Statement. No court decisions, appeals, or administrative tribunal findings are cited in the instrument itself.

That absence does not mean litigation will not occur. As with other Repatriation Medical Authority Statements, administrative decisions that rely on this Statement may be the subject of internal review, merits review before the Veterans Review Board or the Administrative Appeals Tribunal as applicable under statutory pathways, and judicial review in superior courts on questions of law and procedural fairness. However, none of those mechanisms, outcomes, or precedents are contained in this instrument, and no cases are named. Any litigation history relevant to interpretation or application of this instrument would therefore arise after its commencement and would need to be located in case law databases or administrative tribunal records rather than in the instrument text.

Practitioners should treat the present Statement as the authoritative Repatriation Medical Authority view as at 27 March 2023. If litigation arises, it will likely focus on how the factors and definitions in s 9 and Schedule 1 are applied to particular medical facts, the sufficiency of evidence to demonstrate the temporal relationships required under s 10, and the interaction with other Statements under s 11. The instrument itself contains no litigation guidance, no binding precedent statements, and no internal appeals process; those procedural matters remain within the statutory frameworks of the VEA and MRCA and the general administrative law system.

The Statement contains many specific, technical provisions that create potential pitfalls for claimants, medical practitioners and decision makers. These are not legal judgments; they are pragmatic attention points derived directly from the instrument’s wording.

1. Temporal precision matters. Many factors in s 9 have explicit time windows and duration requirements. For example, diabetes must have existed for at least 5 years before clinical onset or worsening (s 9(9), 9(28)); dyslipidaemia must be present before age 65 and before onset/worsening (s 9(4), 9(23)); smoking must meet a minimum of 10 pack‑years and must have commenced at least 5 years before onset/worsening, and if smoking ceased the onset/worsening must be within 20 years of cessation (s 9(10), 9(29)). Obesity requires at least 5 years within a 20 year window (s 9(12), 9(31)). Failure to document precise dates can mean a factor is not accepted as meeting the minimum. The definitions in Schedule 1 give precise calculations for BMI and pack‑years which must be used.

2. Neuroimaging timing is ambiguous but consequential. Neuroimaging is defined as an image “usually obtained at a date after the clinical onset of the disease” (Schedule 1). The factors in s 9(2) and s 9(21) require specified diseases of the cerebral vessels “in the presence of neuroimaging … findings” before onset or before worsening. In practice decision makers may require contemporaneous imaging or will need to be satisfied that later imaging reliably reflects prior pathology. Claimants should obtain and preserve imaging reports and, where available, date‑stamped imaging studies.

3. DSM‑5‑TR dependence. The core diagnostic standard is DSM‑5‑TR based for major and mild neurocognitive disorder (s 7(2), Schedule 1). The Schedule requires standardised neuropsychological testing or another qualified clinical assessment to document substantial or modest impairment (Schedule 1 definitions for major and mild neurocognitive disorder). Absent properly conducted neuropsychological assessments and clear clinician statements on independence in activities of daily living, a diagnosis under the Statement may fail the DSM‑based threshold.

4. Exclusions require careful differential diagnosis. Subsection 7(2)E lists multiple exclusions that, if primary, mean the deficits are not due to vascular neurocognitive disorder: delirium, another mental disorder, inherited diffuse white matter disease, neurodegenerative disease (for example Alzheimer disease), brain tumour, subdural haematoma, effects of a substance, or systemic disorders such as hypothyroidism or vitamin B12 deficiency. Claimants and clinicians must therefore document investigations excluding these causes where relevant.

5. Environmental exposure evidentiary burden. Inhaling ambient, chronically polluted air is a listed factor if exposure was for at least 1,000 hours within the 5 years before onset/worsening and the air meets PM2.5 thresholds (s 9(16), s 9(35) and Schedule 1). Establishing that a claimant met the 1,000 hour threshold and that the air quality metric applies in the relevant location may require environmental monitoring data, employment records, or expert evidence.

6. Overlap with other Statements creates jurisdictional complexity. Section 11 forces cross‑application where a factor refers to an injury or disease covered by another Statement. Practitioners must identify relevant overlapping Statements and ensure evidence meets the other Statements’ terms; failure to do so may leave a factor unproven.

7. The “inability to obtain appropriate clinical management” factor is open textured. Section 9(39) allows inability to obtain appropriate clinical management to raise a reasonable hypothesis. The instrument provides no definition of what counts as “appropriate” or how lack of access is to be proved. Evidence of referral patterns, wait times, proximity to specialist services, and documented denial of care may therefore become necessary in some claims.

8. Distinguishing “onset” from “worsening” and “arising out of” service. Section 10(2) clarifies that subsections 9(20)-9(39) are limited to material contribution or aggravation where the disorder was suffered or contracted before or during, but did not arise out of, relevant service. This requires precise factual sequencing: was the disorder caused by service, or did it pre‑exist and then worsen with service exposure? That factual distinction affects which part of s 9 applies.

9. Numerical thresholds that may not fit clinical reality. Some thresholds are absolute: BMI ≥ 30 for obesity; HDL < 1.0 mmol/L, LDL > 4.0 mmol/L, triglycerides ≥ 2.0 mmol/L, total cholesterol > 5.5 mmol/L for dyslipidaemia (Schedule 1). Patients whose laboratory values fluctuate around these thresholds may fall into evidentiary gaps despite clinically significant dyslipidaemia.

10. ICD‑10‑AM coding is secondary. Although s 7(3) notes ICD‑10‑AM code F01 applies for vascular neurocognitive disorder, the instrument insists that the definition for application is the DSM‑derived one in s 7(2). Reliance solely on ICD coding without DSM‑based diagnostic documentation may therefore be insufficient.

These “gotchas” point to the practical risk that claims will be lost due to narrow evidentiary failures rather than on medical merit. They also indicate where claim preparation should focus: clear dates, quantitative test results, imaging records, specialist reports, and documentation excluding other causes.

For practitioners preparing or supporting claims, compliance means assembling evidence that maps directly to the instrument’s factors and definitions. Below is a practical, source‑grounded checklist and procedural guide based on the instrument’s text.

1. Confirm jurisdictional applicability. Verify the claim falls within section 120A of the VEA or section 338 of the MRCA, as this Statement applies only to those claims (s 5). If a claimant’s claim is outside these statutory hooks, the Statement will not apply.

2. Establish the clinical diagnosis using DSM‑5‑TR criteria. The core definition comes from DSM‑5‑TR and requires either major or mild neurocognitive disorder as defined in Schedule 1 (s 7(2), Schedule 1). Obtain standardised neuropsychological testing where feasible to document substantial or modest impairment, and obtain clinician statements about interference with daily living for major disorder.

3. Document vascular aetiology and cerebrovascular disease. The definition requires clinical features consistent with a vascular aetiology and evidence of cerebrovascular disease from history, examination, or neuroimaging sufficient to account for deficits (s 7(2) B-C). Secure hospital discharge summaries for documented cerebrovascular events, stroke certificates, neurology reports, and dated neuroimaging (MRI or CT) reports identifying white matter lesions, haemorrhage or infarction where relevant (s 9(2), 9(21)).

4. Map claimant facts to the s 9 factor list. Work through s 9(1)-(19) for onset claims and s 9(20)-(38) for worsening claims. Collect documentary evidence for each applicable factor:

   • Cerebrovascular accident or subarachnoid haemorrhage: acute admission records, imaging, discharge diagnosis (s 9(1), 9(20)).
   • Specified disease of cerebral vessels: pathology reports or specialist diagnosis and neuroimaging showing white matter change, hemorrhage or infarction (s 9(2), s 9(21); Schedule 1 list of specified diseases).
   • Hypertension: medical records showing diagnostic dates and treatment before onset/worsening (s 9(3), s 9(22)).
   • Dyslipidaemia: lipid results meeting Schedule 1 thresholds or records of lipid‑lowering therapy, and evidence that dyslipidaemia existed before age 65 (s 9(4), s 9(23); Schedule 1).
   • Cardiac arrhythmias and cardiac disease: ECGs, cardiology letters, records of atrial fibrillation, heart failure or ischaemic heart disease (s 9(5), s 9(7), s 9(24), s 9(26)).
   • Cardiac surgery: operative and hospital records establishing timing within 12 months prior to onset/worsening (s 9(8), s 9(27)).
   • Diabetes duration: GP records showing diagnosis date and treatment for at least 5 years before onset/worsening (s 9(9), s 9(28)).
   • Smoking: detailed smoking history enabling pack‑year calculation; use Schedule 1 method to compute pack‑years and document cessation dates where relevant (s 9(10), s 9(29); Schedule 1).
   • Physical activity capacity: occupational health and clinical notes describing METs capacity or exercise tolerance; consider functional testing records (s 9(11), s 9(30); Schedule 1 MET definition).
   • Obesity: serial weight and height records showing BMI ≥ 30 for at least 5 years within 20 years (s 9(12), s 9(31); Schedule 1 BMI formula).
   • Depression and PTSD: psychiatric records showing diagnosis dates at least 5 years before onset/worsening (s 9(13), s 9(14), s 9(32), s 9(33)).
   • Chronic kidney disease: laboratory records for GFR < 60 for 3 months, albuminuria data, renal imaging/biopsy, or transplant history (s 9(15), s 9(34); Schedule 1).
   • Ambient pollution exposure: employment location histories, environmental monitoring data showing PM2.5 > 25 µg/m3, and time quantification to meet 1,000 hours in 5 years (s 9(16), s 9(35); Schedule 1).
   • Migraine: neurology or GP notes documenting frequency and duration (s 9(17), s 9(36)).
   • Traumatic brain injury: hospital or ED records classifying TBI severity and dates at least 5 years before onset/worsening (s 9(18), s 9(37)).
   • Orthostatic hypotension: measured blood pressures demonstrating the stipulated drop within 3 minutes of postural change, occurring at least once yearly for at least 5 years in 20 years (s 9(19), s 9(38); Schedule 1).

5. Address differential diagnosis and exclusions. Where other causes listed in s 7(2)E could account for deficits, obtain appropriate investigations to rule them out: delirium screens, psychiatric assessments, B12 and folate testing, thyroid function tests, neurosyphilis testing, HIV testing when indicated, brain imaging for tumours or subdural haematoma, and genetic testing where relevant.

6. Establish relationship to relevant service. Section 10 requires that any s 9 factor be related to the person’s relevant service. Collate service service records, deployment histories, incident reports, and medical records from service time showing onset, exposure, or treatment correlated with the factor. For material contribution or aggravation claims where the disorder pre‑existed service, ensure the claim demonstrates the worsening occurred in a way linked to service per s 10(2).

7. Where a factor overlaps with another Statement, follow that Statement. If any factor refers to an injury or disease covered by another Statement of Principles, identify that Statement and prepare evidence in accordance with its terms (s 11). Cross‑reference specialist statements early to avoid proof gaps.

8. Prepare medico‑legal evidence and nexus opinions. Expert reports should do three things: document the DSM‑5‑TR diagnostic standard has been met, identify which s 9 factors are present with reference to Schedule 1 definitions, and express an opinion on whether those factors are related to the person’s relevant service. Where clinical onset versus worsening is material, the expert should date events and explain the temporal relationship.

9. Anticipate data gaps and use corroborative records. Where historic data are incomplete, search hospital records, pension files, service medical records, family statements, employer records and pharmacy dispensing histories to reconstruct timelines. For environmental exposures, obtain local environmental agency records or employer air monitoring logs.

10. Where access to management is an issue, document systemic barriers. If relying on s 9(39), gather evidence of referral attempts, wait lists, geographic service deserts, denial letters, or other documentation showing inability to obtain management.

11. Use the Schedule definitions in evidence. Ensure calculations for BMI, pack‑years, and METs follow the Schedule 1 formulas and thresholds so that decision makers can directly apply the instrument’s definitions.

12. Record imaging dates carefully. Because neuroimaging is described as often obtained after clinical onset (Schedule 1) and because s 9 factors require these imaging findings to pre‑date onset or worsening in some instances, practitioners should explain the medical rationale as to why later imaging reflects earlier pathology if earlier imaging is unavailable.

13. Maintain contemporaneous clinical notes and cross‑reference. Clinicians should ensure their records are clear on dates, diagnostic reasoning, and functional status statements useful for the DSM‑based diagnosis and for determining independence in daily activities for major neurocognitive disorder.

Following these steps will ensure evidence aligns with the instrument’s text. The Statement of Principles provides precise thresholds and criteria; compliance means evidence must be capable of being mapped to those thresholds rather than relying on general clinical impressions.